Author

A. Renslo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1

Frequent Co-Authors

A. B. Olshen· 1 shared A. Mondal· 1 shared B. C. Hann· 1 shared C. Bryant· 1 shared D. L. Minor· 1 shared e. collisson· 1 shared E. Y. Isacoff· 1 shared H. Black· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. Olshen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of covalent chemogenetic K2P channel activators

P. E. Deal, H. Lee, A. Mondal, M. Lolicato, P. R. Furtado de Mandonca, H. Black, X. El-Hilali, C. Bryant, E. Y. Isacoff, A. Renslo, D. L. Minor

This paper develops a chemogenetic method to irreversibly activate K2P channels, enabling studies of their function and potential therapeutic applications.

bioRxiv · Oct 15, 2023Biophysics

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz, A. B. Olshen, I. Yeh, B. C. Hann, N. Zhao, Y.-h. Wang, J. Korkola, S. C. Behr, M. J. Evans, e. collisson, A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

bioRxiv · May 12, 2020Cancer Biology